[1]
|
Miller, K.D., Ostrom, Q.T., Kruchko, C., Patil, N., Tihan, T., Cioffi, G., et al. (2021) Brain and Other Central Nervous System Tumor Statistics, 2021. CA: A Cancer Journal for Clinicians, 71, 381-406. https://doi.org/10.3322/caac.21693
|
[2]
|
Ferrari, A.J., Santomauro, D.F., Aali, A., Abate, Y.H., Abbafati, C., Abbastabar, H., et al. (2024) Global Incidence, Prevalence, Years Lived with Disability (YLDs), Disability-Adjusted Life-Years (DALYs), and Healthy Life Expectancy (HALE) for 371 Diseases and Injuries in 204 Countries and Territories and 811 Subnational Locations, 1990-2021: A Systematic Analysis for the Global Burden of Disease Study 2021. The Lancet, 403, 2133-2161. https://doi.org/10.1016/s0140-6736(24)00757-8
|
[3]
|
Ostrom, Q.T., Price, M., Neff, C., Cioffi, G., Waite, K.A., Kruchko, C., et al. (2023) CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2016-2020. Neuro-Oncology, 25, iv1-iv99. https://doi.org/10.1093/neuonc/noad149
|
[4]
|
Kannan, S., Murugan, A.K., Balasubramanian, S., Munirajan, A.K. and Alzahrani, A.S. (2022) Gliomas: Genetic Alterations, Mechanisms of Metastasis, Recurrence, Drug Resistance, and Recent Trends in Molecular Therapeutic Options. Biochemical Pharmacology, 201, Article ID: 115090. https://doi.org/10.1016/j.bcp.2022.115090
|
[5]
|
Huang, D., Wang, Z., He, X., Diplas, B.H., Yang, R., Killela, P.J., et al. (2015) Recurrent TERT Promoter Mutations Identified in a Large-Scale Study of Multiple Tumour Types Are Associated with Increased TERT Expression and Telomerase Activation. European Journal of Cancer, 51, 969-976. https://doi.org/10.1016/j.ejca.2015.03.010
|
[6]
|
Palsgrove, D.N., Taheri, D., Springer, S.U., Cowan, M., Guner, G., Mendoza Rodriguez, M.A., et al. (2019) Targeted Sequencing of Plasmacytoid Urothelial Carcinoma Reveals Frequent TERT Promoter Mutations. Human Pathology, 85, 1-9. https://doi.org/10.1016/j.humpath.2018.10.033
|
[7]
|
Di Nunno, V., Aprile, M., Bartolini, S., Gatto, L., Tosoni, A., Ranieri, L., et al. (2023) The Biological and Clinical Role of the Telomerase Reverse Transcriptase Gene in Glioblastoma: A Potential Therapeutic Target? Cells, 13, Article No. 44. https://doi.org/10.3390/cells13010044
|
[8]
|
He, Y., Jiang, K., Liu, B., Meng, H. and Li, Z. (2024) Spatiotemporal Control of Dnazyme Activity for Fluorescent Imaging of Telomerase RNA in Living Cells. Analytica Chimica Acta, 1287, Article ID: 342085. https://doi.org/10.1016/j.aca.2023.342085
|
[9]
|
Perevalova, A.M., Gulyaeva, L.F. and Pustylnyak, V.O. (2024) Roles of Interferon Regulatory Factor 1 in Tumor Progression and Regression: Two Sides of a Coin. International Journal of Molecular Sciences, 25, Article No. 2153. https://doi.org/10.3390/ijms25042153
|
[10]
|
Yang, Z. and Zhang, X. (2024) The Clinical and Molecular Landscape of Rosette-Forming Glioneuronal Tumors. Biomedicines, 12, Article No. 2325. https://doi.org/10.3390/biomedicines12102325
|
[11]
|
魏志敏, 李子帅, 刘文斌, 等. 端粒酶反转录酶在肿瘤发生和发展中的作用机制[J]. 肿瘤, 2023, 43(5): 448-456.
|
[12]
|
郭晓强, 黄卫人, 蔡志明, 等. 端粒酶基因突变与癌症发生[J]. 科学通报, 2015, 60(28): 2790-2793.
|
[13]
|
Pennisi, G., Bruzzaniti, P., Burattini, B., Piaser Guerrato, G., Della Pepa, G.M., Sturiale, C.L., et al. (2024) Advancements in Telomerase-Targeted Therapies for Glioblastoma: A Systematic Review. International Journal of Molecular Sciences, 25, Article No. 8700. https://doi.org/10.3390/ijms25168700
|
[14]
|
Walsh, K.M., Wiencke, J.K., Lachance, D.H., Wiemels, J.L., Molinaro, A.M., Eckel-Passow, J.E., et al. (2015) Telomere Maintenance and the Etiology of Adult Glioma. Neuro-Oncology, 17, 1445-1452. https://doi.org/10.1093/neuonc/nov082
|
[15]
|
加潇坤, 彭冲奇, 赵振宇, 等. 脑胶质瘤WHO中枢神经系统肿瘤分类(第五版)分析: 附60例报告[J]. 中国现代神经疾病杂志, 2022, 22(12): 1086-1093.
|
[16]
|
Powter, B., Jeffreys, S.A., Sareen, H., Cooper, A., Brungs, D., Po, J., et al. (2021) Human TERT Promoter Mutations as a Prognostic Biomarker in Glioma. Journal of Cancer Research and Clinical Oncology, 147, 1007-1017. https://doi.org/10.1007/s00432-021-03536-3
|
[17]
|
Ozair, A., Bhat, V., Alisch, R.S., Khosla, A.A., Kotecha, R.R., Odia, Y., et al. (2023) DNA Methylation and Histone Modification in Low-Grade Gliomas: Current Understanding and Potential Clinical Targets. Cancers, 15, Article No. 1342. https://doi.org/10.3390/cancers15041342
|
[18]
|
Heidenreich, B. and Kumar, R. (2017) TERT Promoter Mutations in Telomere Biology. Mutation Research/Reviews in Mutation Research, 771, 15-31. https://doi.org/10.1016/j.mrrev.2016.11.002
|
[19]
|
郑义, 宋莱荣, 徐晓颖, 等. 人胶质母细胞瘤细胞系Y1203的构建及应用[J]. 首都医科大学学报, 2023, 44(5): 733-740.
|
[20]
|
张科平, 许洁, 林丹义, 等. TERT启动子突变检测在胶质瘤中的意义[J]. 诊断病理学杂志, 2022, 29(7): 628-630, 634.
|
[21]
|
Vinagre, J., Pinto, V., Celestino, R., Reis, M., Pópulo, H., Boaventura, P., et al. (2014) Telomerase Promoter Mutations in Cancer: An Emerging Molecular Biomarker? Virchows Archiv, 465, 119-133. https://doi.org/10.1007/s00428-014-1608-4
|
[22]
|
Shalaby, T., Hiyama, E. and Grotzer, M.A. (2010) Telomere Maintenance as Therapeutic Target in Embryonal Tumours. Anti-Cancer Agents in Medicinal Chemistry, 10, 196-212. https://doi.org/10.2174/1871520611009030196
|
[23]
|
Yong, V.W., Power, C., Forsyth, P. and Edwards, D.R. (2001) Metalloproteinases in Biology and Pathology of the Nervous System. Nature Reviews Neuroscience, 2, 502-511. https://doi.org/10.1038/35081571
|
[24]
|
国家卫生健康委员会医政医管局, 中国抗癌协会脑胶质瘤专业委员会, 中国医师协会脑胶质瘤专业委员会. 脑胶质瘤诊疗指南(2022版) [J]. 中华神经外科杂志, 2022, 38(8): 757-777.
|
[25]
|
Rodriguez, F.J., Vizcaino, M.A. and Lin, M. (2016) Recent Advances on the Molecular Pathology of Glial Neoplasms in Children and Adults. The Journal of Molecular Diagnostics, 18, 620-634. https://doi.org/10.1016/j.jmoldx.2016.05.005
|
[26]
|
Rudà, R., Pellerino, A. and Soffietti, R. (2024) Blood and Cerebrospinal Fluid Biomarkers in Neuro-Oncology. Current Opinion in Neurology, 37, 693-701. https://doi.org/10.1097/wco.0000000000001317
|
[27]
|
Vuong, H.G., Altibi, A.M.A., Duong, U.N.P., Ngo, H.T.T., Pham, T.Q., Chan, A.K., et al. (2017) TERT Promoter Mutation and Its Interaction with IDH Mutations in Glioma: Combined TERT Promoter and IDH Mutations Stratifies Lower-Grade Glioma into Distinct Survival Subgroups—A Meta-Analysis of Aggregate Data. Critical Reviews in Oncology/Hematology, 120, 1-9. https://doi.org/10.1016/j.critrevonc.2017.09.013
|
[28]
|
Singh, G., Singh, A., Bae, J., Manjila, S., Spektor, V., Prasanna, P., et al. (2024) New Frontiers in Domain-Inspired Radiomics and Radiogenomics: Increasing Role of Molecular Diagnostics in CNS Tumor Classification and Grading Following WHO CNS-5 Updates. Cancer Imaging, 24, Article No. 133. https://doi.org/10.1186/s40644-024-00769-6
|
[29]
|
Mo, Z., Xin, J., Chai, R., Woo, P.Y.M., Chan, D.T.M. and Wang, J. (2022) Epidemiological Characteristics and Genetic Alterations in Adult Diffuse Glioma in East Asian Populations. Cancer Biology & Medicine, 19, 1440-1459. https://doi.org/10.20892/j.issn.2095-3941.2022.0418
|
[30]
|
Barritault, M., Meyronet, D. and Ducray, F. (2018) Molecular Classification of Adult Gliomas: Recent Advances and Future Perspectives. Current Opinion in Oncology, 30, 375-382. https://doi.org/10.1097/cco.0000000000000482
|
[31]
|
Menyhárt, O. and Győrffy, B. (2019) Principles of Tumorigenesis and Emerging Molecular Drivers of SHH‐Activated Medulloblastomas. Annals of Clinical and Translational Neurology, 6, 990-1005. https://doi.org/10.1002/acn3.762
|
[32]
|
Appin, C.L. and Brat, D.J. (2015) Biomarker-Driven Diagnosis of Diffuse Gliomas. Molecular Aspects of Medicine, 45, 87-96. https://doi.org/10.1016/j.mam.2015.05.002
|
[33]
|
Brandner, S. and von Deimling, A. (2015) Diagnostic, Prognostic and Predictive Relevance of Molecular Markers in Gliomas. Neuropathology and Applied Neurobiology, 41, 694-720. https://doi.org/10.1111/nan.12246
|
[34]
|
Wu, L., Fidan, K., Um, J. and Ahn, K.S. (2020) Telomerase: Key Regulator of Inflammation and Cancer. Pharmacological Research, 155, Article ID: 104726. https://doi.org/10.1016/j.phrs.2020.104726
|
[35]
|
王雷明, 王玮, 刘莉, 等. 成人IDH野生型弥漫性胶质瘤的临床病理学及分子遗传学特征[J]. 中华病理学杂志, 2021, 50(7): 734-739.
|